CCND2: A Potential Drug Target for Cancer (G894)
CCND2: A Potential Drug Target for Cancer
Cancer cell navigation (CCND2) is a critical process that enables cancer cells to survive and grow in an environment that is hostile to the body. CCND2 is a protein that is expressed in various tissues and cells of the human body, including the brain, spinal cord, and blood vessels. It plays a vital role in cell navigation, and it is also a potential drug target for various diseases, including cancer.
The Importance of CCND2 in Cancer Cells
CCND2 is a 21-kDa protein that is expressed in various tissues and cells of the human body. It is highly expressed in the brain, and it is also found in the blood vessels, including the microvascular endothelial cells (MECs) and the pericytes. CCND2 is involved in the regulation of cell migration, invasion, and metastasis. It is also involved in the regulation of cell survival and apoptosis.
In cancer, CCND2 is involved in the regulation of cancer cell growth, invasion, and metastasis. It is a critical factor for the development and progression of cancer. For example, CCND2 is expressed in various types of cancer, including breast, ovarian, and colorectal cancers. It is also involved in the regulation of cancer cell invasion and metastasis, which is a critical step in the development of cancer.
CCND2 as a Drug Target
CCND2 is a potential drug target for various diseases, including cancer. Researchers have identified several potential drug targets for CCND2, including the regulation of cell migration, invasion, and metastasis.
One potential drug target for CCND2 is the inhibition of its activity. Researchers have found that the activity of CCND2 is regulated by various factors, including tyrosine kinase signaling pathways, mitochondrial dysfunction, and cellular signaling pathways. Therefore, inhibitors that target these pathways may be effective in inhibiting the activity of CCND2.
Another potential drug target for CCND2 is the modulation of its expression levels. Researchers have found that various factors, including pharmacological agents, genetic modifiers, and cellular signaling pathways, can modulate the expression levels of CCND2. Therefore, drugs that can modulate the expression levels of CCND2 may be effective in targeting it.
CCND2 as a Biomarker
CCND2 may also be used as a biomarker for various diseases, including cancer. Its expression is regulated by various factors, including tyrosine kinase signaling pathways, mitochondrial dysfunction, and cellular signaling pathways. Therefore, the level of CCND2 expression may be affected by various diseases, including cancer.
Research has shown that the expression levels of CCND2 are affected by various types of cancer, including breast, ovarian, and colorectal cancers. Therefore, CCND2 may be a useful biomarker for these cancers. It is also possible that CCND2 may be used as a biomarker for other diseases, including cancer.
Conclusion
In conclusion, CCND2 is a protein that is involved in the regulation of cell navigation (CCND2) and the development and progression of cancer. It is a potential drug target for various diseases, including cancer. Its expression is regulated by various factors, including tyrosine kinase signaling pathways, mitochondrial dysfunction, and cellular signaling pathways. Therefore, inhibitors that target these pathways or modulators that modulate the expression levels of CCND2 may be effective in targeting it. CCND2 may also be used as a biomarker for various diseases, including cancer. Further research is needed to fully understand the role of CCND2 in cell navigation and the development and progression of cancer.
Protein Name: Cyclin D2
Functions: Regulatory component of the cyclin D2-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition (PubMed:8114739, PubMed:18827403). Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase (PubMed:8114739, PubMed:18827403). Hypophosphorylates RB1 in early G(1) phase (PubMed:8114739, PubMed:18827403). Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals (PubMed:8114739, PubMed:18827403)
The "CCND2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCND2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28
